Figure 6.

In vivo efficacy of NSC697923 on human NB xenografts. (a) At the end of the indicated treatment schedules, SH-SY5Y xenografted tumors and tumor weights from control (N=4) and treatment groups (N=4) were presented. (b) At the end of the indicated treatment schedules, NGP xenografted tumors and tumor weights from control (N=3) and treatment groups (N=3) were presented. P-value <0.05 (*) was indicated. (c) The working model for UBE2N inhibitor NSC697923-mediated NB cell apoptosis. In p53 wild-type NB cells, UBE2N inhibition blocks cytoplasm transportation of p53, increases its nuclear accumulation, and leads to p53-mediated apoptosis. While in p53 mutant NB cells, NSC697923 induces JNK phosphorylation and activates JNK-mediated apoptosis. Data from a and b are representative of two independent experiments